Update and rationale for ongoing acute myocardial infarction trials: Combination therapy, facilitation, and myocardial preservation - 17/08/11
Doi : 10.1016/j.ahj.2006.04.011
Howard C. Herrmann, MD ⁎ 
Cardiac Catheterization Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA
⁎Reprint requests: Howard C. Herrmann, MD, Director, Cardiac Catheterization Laboratories, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104.
Résumé |
Advancements in the treatment of myocardial infarction such as coronary care units, patient education, improved emergency response systems, and reperfusion therapy have reduced mortality. However, in an effort to further reduce the present rate by improving patency rates and microcirculatory perfusion, by better preserving myocardium, and/or treating shock more effectively, more research is under way to improve strategies now in place and to develop new, more effective ways to treat these patients.
Le texte complet de cet article est disponible en PDF.Plan
© 2006
Publié par Elsevier Masson SAS.
Vol 151 - N° 6S
P. S30-S39 - juin 2006 Retour au numéro
Article précédent
- Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction
- Duane S. Pinto, Matthew Southard, Lauren Ciaglo, C. Michael Gibson
- To obtain continuing medical education credit
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?